NCT00676533View on ClinicalTrials.gov

Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections

PHASE4CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

January 31, 2004

Conditions
Urinary Tract Infection
Interventions
DRUG

Cipro XR (Ciprofloxacin, BAYQ3939)

3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.

Trial Locations (40)

13031

Camillus

19053

Feasterville

21210

Baltimore

29681

Simpsonville

30094

Conyers

30214

Fayetteville

30308

Atlanta

30342

Atlanta

32216

Jacksonville

32605

Gainesville

32626

Chiefland

33407

West Palm Beach

33607

Tampa

34474

Ocala

35205

Birmingham

35801

Huntsville

36078

Tallassee

36106

Montgomery

47713

Evansville

48109

Ann Arbor

77566

Lake Jackson

83835

Hayden

84109

Salt Lake City

84121

Salt Lake City

85014

Phoenix

85201

Mesa

85282

Tempe

91345

Mission Hills

92117

San Diego

92128

San Diego

92886

Yorba Linda

93710

Fresno

97404

Eugene

99216

Spokane

85225-2909

Chandler

92182-4701

San Diego

06001

Avon

21108-1571

Millersville

07202-3672

Elizabeth

98105-5221

Seattle

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00676533 - Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections | Biotech Hunter | Biotech Hunter